Drugs / LEU011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06193902 | Nov 2023 → May 2029 expected | — | Leucid Bio | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Leucid Bio | Results Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours leucid.com ↗
Preliminary data from the ongoing AERIAL trial have established proof-of-concept for LEU011 by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. |
| 2023-09-21 | Leucid Bio | Regulatory Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011 leucid.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEU011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06193902 ↗ |
| Modality | Cell therapy | “autologous CAR T cells targeting NKG2D ligands” NCT06193902 ↗ |
| Route | Intravenous | “Subjects will receive LEU011 as a single IV dose” NCT06193902 ↗ |